biostudies-literatureSchnabel RBBristol Myers Squibb-Pfizer AllianceGerman Research FoundationGerman Ministry of Education and Research, Berlin, GermanyUnion's Horizon 2020 research and innovation programmeCanadian Institutes of HealthResearchBMBFGerman Ministry of Research and EducationDaiichi Sankyo EuropeAccelerating Clinical Trials NetworkPopulation Health Research InstituteERACoSysMed3Leducq FoundationDutch Heart FoundationEuropean Union's Horizon Europe research and innovation programmeAFFECT EUBritish Heart FoundationMedtronicHamilton Health SciencesWolfgang Seefried project funding German Heart FoundationHeart and Stroke Foundation of CanadaEuropean Union CATCH MEGerman Centre for Cardiovascular ResearchGerman Centre for Cardiovascular Research, Berlin, GermanyEuropean Union's Horizon 2020 research and innovation programmeMAESTRIACanadian Stroke Prevention Intervention Network4902-4916https://www.ebi.ac.uk/biostudies/studies/S-EPMC11631065biostudies-literatureUnknown45(46)<h4>Background and aims</h4>The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.<h4>Methods</h4>These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and deatEuropean heart journalAnticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.PMC11631065847770633196FKZ 81X2800182101095480201610PTJ-378238Ki 509167694BMBF 01ZX1408A64813101-002-2022-0118965286031L0239AA/18/2/34218Schnabel RBZapf AMarijon EVardas PHealey JSErath JWSimantirakis ESchotten UKutyifa VCamm AJAtar DSehner SRivard LLinde CBecher NLopes RDBenezet-Mazuecos JMabo PChlouverakis GDichtl WToennis TLee SFBlomstrom-Lundqvist CLip GYHBertaglia EMcIntyre WFFierenz AGoette AAlings MBirnie DHBenz APKirchhof PGranger CBfalseAnticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.<h4>Background and aims</h4>The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.<h4>Methods</h4>These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and deat2024-01-01T00:00:00Z2024 Dec2025-04-26T23:12:51.811Z2025-04-06T17:30:55.59ZS-EPMC116310653922201810.1093/eurheartj/ehae596